Trials / Unknown
UnknownNCT03064243
A Phase II Study of Apatinib in STS Patients
Effectiveness and Safety of Apatinib for the Patients With Advanced Soft Tissue Sarcoma
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 53 (estimated)
- Sponsor
- Shanghai Jiao Tong University Affiliated Sixth People's Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Apatinib is a kind of innovative medicines approved by China Food and Drug Administration（CFDA）, which was researched by Jiangsu Hengrui Pharmaceutical Co., Ltd. Apatinib is a kinase inhibitor of receptor tyrosine with VEGFR2. The protocol is to explore Apatinib for the effectiveness of advanced soft tissue sarcoma and safety.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | apatinib | apatinib 500mg po. qd. |
Timeline
- Start date
- 2017-03-01
- Primary completion
- 2018-03-01
- Completion
- 2018-09-01
- First posted
- 2017-02-27
- Last updated
- 2017-02-27
Source: ClinicalTrials.gov record NCT03064243. Inclusion in this directory is not an endorsement.